Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/07/2006US20060276405 Methods for treating hepatitis C
12/07/2006US20060276404 Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
12/07/2006US20060276394 Methods and compositions for treating neurological disorders
12/07/2006US20060276393 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
12/07/2006US20060276391 Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
12/07/2006US20060276390 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
12/07/2006US20060276378 Methods and pharmaceutical compositions for treating sepsis
12/07/2006US20060276374 Use of an agent that restores tissue perfusion and oxygenation
12/07/2006US20060276373 Neuroprotective complex for treatment of cerebral ischemia and injury
12/07/2006US20060276372 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
12/07/2006US20060276339 Methods and compositions for increasing the efficacy of biologically-active ingredients
12/07/2006US20060275909 Nutrition formulations and methods of providing nutrition formulations
12/07/2006US20060275796 Canine herpesvirus thymidine kinase nucleic acid molecules
12/07/2006US20060275742 Cardioplegic solution
12/07/2006US20060275517 Compositions of natural products and use thereof
12/07/2006US20060275516 Compositions and methods for the treatment of allergic rhinitis
12/07/2006US20060275513 Diet supplement for burning additional calories, providing sustained energy, supporting weight loss, and/or improving mental focus
12/07/2006US20060275512 Combined effects of nutrients on proliferation of stem cells
12/07/2006US20060275506 Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
12/07/2006US20060275504 Methods and compositions for augmenting cancer chemotherapeutic agents
12/07/2006US20060275503 Such as strontium ranelate in combination with a drug that reduces the incidence of bone fracture and/or increases bone density and/or improves healing of fractured bone, such as a SERM, vitamin D2/D3, or parathyroid hormone; tablets
12/07/2006US20060275376 Microcapsules with modified release of active principles with low solubility for oral delivery
12/07/2006US20060275372 Nanoparticulate imatinib mesylate formulations
12/07/2006US20060275370 Method and compositions for treatment of epithelial damage
12/07/2006US20060275368 Biocompatible polymer
12/07/2006US20060275367 Extended release formulations
12/07/2006US20060275366 Controlled-release formulation
12/07/2006US20060275365 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/07/2006US20060275363 Stable granulates containing s-adenosylmethionine and process for preparation thereof
12/07/2006US20060275362 Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
12/07/2006US20060275360 Oral dosage forms comprising progesterone and methods of making and using the same
12/07/2006US20060275357 Organic compounds
12/07/2006US20060275356 Pharmaceutical compositions for treating or preventing coronary artery disease
12/07/2006US20060275352 Device for transdermal electrotransport delivery of fentanyl and sufentanil
12/07/2006US20060275346 Liquid seasoning
12/07/2006US20060275343 The applicator assembly includes a sleeve that encases a swab having a portion that contacts a gelled composition; sleeve is manually severed to expose the applicator and the composition; gelled matrix containing, glycerin, NaCl, hydroxyethyl cellulose, zinc gluconate, benzalkonium chloride, and NaOH
12/07/2006US20060275340 Biocompatible controlled release coatings for medical devices and related methods
12/07/2006US20060275339 Use of antiseptic active principles in pmma bone cements
12/07/2006US20060275337 Complex coacervate core micelles as surface modification or surface treatment
12/07/2006US20060275334 Parasiticidal composition
12/07/2006US20060275333 Composition with beads for treatment of contact dermatitis
12/07/2006US20060275331 Pharmaceutical composition, method of manufacturing and therapeutic use thereof
12/07/2006US20060275321 Polypeptide antagonists of HIV-1 Tat protein
12/07/2006US20060275308 Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
12/07/2006US20060275306 lyophilized mixture of a recombinant humanized HER2 monoclonal antibody, a lyoprotectant, and a buffer; physical and chemical stability and integrity upon lyophilization and storage; breast cancer
12/07/2006US20060275305 HERCEPTIN adjuvant therapy
12/07/2006US20060275303 Modulating angiogenesis using LL-37/HCAP-18
12/07/2006US20060275294 Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
12/07/2006US20060275284 Combination therapy for treatment of autoimmune diseases using b-cell depleting/immunoregulatory antibody combination
12/07/2006US20060275278 Method and ophthalmic formulation for eye protection or treatment
12/07/2006US20060275277 Use of coagulation proteins to lyse clots
12/07/2006US20060275268 Compositions for activating the infiltration activity of dendritic cells, and immunopotentiating agents
12/07/2006US20060275266 Tripeptide of FcyRIIA
12/07/2006US20060275260 Use of imatinib to treat liver disorders and viral infections
12/07/2006US20060275256 Inhibition of pathogenic agents including alpha6beta1 integrin receptor of alpha6beta4 integrin receptor at a surface
12/07/2006US20060275253 Beta hydroxy short to medium chain fatty acid polymer
12/07/2006US20060275252 Moiety is positioned between a water-soluble polymer and a reactive group; water soluble polymer such as polyethylene glycol containing a urethane linkage moiety for example, and a reactive group for conjugating with biodrugs
12/07/2006US20060275251 Polymer complexes of glucuronoglucanes
12/07/2006US20060275250 Reactive polymers and copolymers, method of their preparation and their use
12/07/2006US20060275249 Co-therapy for diabetic conditions
12/07/2006US20060275243 Cosmetic or therapeutic combination preparation with theanine
12/07/2006US20060275237 Skin care compositions containing idebenone
12/07/2006US20060275230 Compositions and methods for treating conditions of the nail unit
12/07/2006US20060275228 Skin care compositions containing idebenone
12/07/2006US20060275214 Methods of screening for anti-inflammatory drugs and use thereof
12/07/2006US20060273819 Antibiotic tetrahydro-beta-carboline derivatives
12/07/2006DE60118395T2 Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen Pharmaceutical compositions of active ingredients with controlled release for the parenteral administration of hydrophilic
12/07/2006DE4323567B4 Aucubin zur Behandlung einer Hepatitis-B-Virus-Infektion Aucubin for treating a hepatitis B virus infection
12/07/2006DE20321227U1 New isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homo erythromycin A useful for treating e.g. bacterial and protozoal infections
12/07/2006DE202005020881U1 Psychostimulans enthaltende pharmazeutische Zusammensetzung Psychostimulant containing pharmaceutical composition
12/07/2006DE10311889B4 Zellpräparat und Verwendung des Präparats zur Behandlung von Gelenken und Knorpeldefekten, sowie Verfahren zur Herstellung Cell preparation and use of the preparation for the treatment of joints and cartilage defects, and methods for preparing
12/07/2006DE102006021572A1 Use of taurolidine for preparing a medicament for preventing/treating e.g. immunodeficiency and autoimmune disorder
12/07/2006DE102005026194A1 Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln N-substituted benzo [d] isoxazol-3-yl-amine derivatives and their use for the preparation of medicaments
12/07/2006DE102005025906A1 Use of a guanylhydrazone compound in the manufacture of medicament for the treatment and/or prevention of e.g. acute and chronic hepatitis, liver cirrhosis, liver cell carcinoma, myocarditis, pharyngitis, pneumonia and pericarditis
12/07/2006DE102005025801A1 Verwendung von Chromonderivaten Use of Chromonderivaten
12/07/2006DE102005025728A1 Polymorphe von Polymorphs of 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
12/07/2006DE102005025625A1 New benzazecine derivatives are dopamine receptor antagonists useful to treat schizophrenia
12/07/2006DE102005025283A1 Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin Stable ingredient complex salts of O-acetylsalicylic acid with basic amino acids and glycine
12/07/2006DE102005025161A1 New pyrimidine- and triazine derivatives are peroxisome proliferator activated receptor modulators, useful to treat e.g. diabetes, insulin resistance, obesity, hyperlipidemia, cardiovascular diseases and Alzheimer's disease
12/07/2006DE102005022977A1 Phenylchinazolinderivate Phenylchinazolinderivate
12/07/2006CA2815780A1 Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
12/07/2006CA2620476A1 Mao-b inhibitors useful for treating obesity
12/07/2006CA2613678A1 Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
12/07/2006CA2611155A1 Combination of hcv protease inhibitors with a surfactant
12/07/2006CA2611147A1 Topical emulsion formulation
12/07/2006CA2611134A1 New derivatives of pyrrolyltriazine together with methods for obtaining them and their use as protecting agents against uv radiation
12/07/2006CA2611133A1 Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
12/07/2006CA2611060A1 Quinoline derivatives as nk3 antagonists
12/07/2006CA2610708A1 Method and composition for transdermal drug delivery
12/07/2006CA2610695A1 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
12/07/2006CA2610694A1 Compositions comrising nebivolol
12/07/2006CA2610692A1 Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
12/07/2006CA2610671A1 Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
12/07/2006CA2610661A1 Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
12/07/2006CA2610644A1 Rnai for control of insects and arachnids
12/07/2006CA2610581A1 Uses of prostacyclin analogs
12/07/2006CA2610575A1 Process for the preparation and isolation of phosphatides
12/07/2006CA2610491A1 Bicyclic derivatives for the treatment of abnormal cell growth
12/07/2006CA2610456A1 3-methanesulfonylquinolines as gaba-b enhancers
12/07/2006CA2610413A1 Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation